Prolia Treatment - Case Study 1 | Osteoporosis | Amgen

Is this your next Prolia® patient?

65-year-old active woman with wrist fracture.
65-year-old active woman
  • Her mother experienced a hip fracture 25 years ago
  • Presents to emergency department with a wrist fracture following a fall

Criteria: Why should she receive Prolia®?

  • The risk of subsequent fracture is more than five times greater within the first year of the initial fracture in postmenopausal women1*
  • Prolia® reduces the risk of subsequent fracture by 39% vs placebo2
  • Prolia® has shown superior increases in bone mineral density as early as 6 months compared with alendronate3
  • Real-world evidence shows greater reduction in fracture rates with Prolia® compared with alendronate4
  • 10 years of Prolia® is associated with a favourable benefit/risk profile:5
    • Sustained low incidence of fractures
    • Continuous increases in bone mineral density
    • Well tolerated
  • Patients prefer the convenient twice-yearly subcutaneous administration of Prolia® injections over oral bisphosphonates6–8
*Compared with the risk of initial fracture.
  1. van Geel TA, et al. Ann Rheum Dis. 2009;68:99–102.
  2. Palacios S, et al. Climacteric. 2015;18:805–12.
  3. Brown JP, et al. J Bone Miner Res. 2009;24:153–61.
  4. Khalid S, et al. Osteoporosis Int. 2017;28(Suppl 1):S64–5. Abstract presented at WCO-IOF-ESCEO 2017; OC21.
  5. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  6. Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
  7. Palacios S, et al. J Clin Endocrinol Metab. 2015;100:E487–92.
  8. Kendler DL, et al. Osteoporos Int. 2011;22:1725–35.


The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public